Results show that although the results of both methods show a statistically significant correlation, the ability of the alternative method to correctly classify individual patients according to glycemic control status is far from optimal.
Glycated hemoglobin (HbA 1c ) is considered the "gold standard" to evaluate the degree of glycemic control in patients with diabetes. 1, 2 From milestone studies such as the Diabetes Control and Complications Trial Research Group (DCCT), a relationship between the levels of HbA 1c and the risk of complications has been established, as has that of such levels and the average blood glucose concentration during the 8 to 10 weeks before sampling. 3 Several methods have been developed to measure the blood levels of HbA 1c in the routine clinical setting, 4, 5 and all of them should be traceable to the one consisting of high-performance liquid chromatography (HPLC), 6 for it is currently considered the reference method of the DCCT [7] [8] [9] and the anchor method of the National Glycohemoglobin Standardisation Program. 10 The validation of alternative techniques should follow a stringent protocol developed by the American Association for Clinical Chemistry, which establishes the relationship of different assays with those of large-scale studies, such as the DCCT; however, this validation protocol is based on the statistical association of 2 or more methods that measure blood levels of HbA 1c , but it overlooks the fact that a single result for the HbA 1c level is used to take an individual decision in a given moment and for a unique patient. 11 The clinician decides if a patient has achieved glycemic control, and, therefore, determines all resulting therapeutic actions based on the interpretation of a single determination of the blood levels of HbA 1c .
With the aim to evaluate the discrepancies between the levels of HbA 1c as determined by HPLC and non-HPLC assays, but mostly to determine the frequency with which those discrepancies lead to different categorization of individual patients in regard to their glycemic control, we undertook a prospective trial whose results emphasize the better clinical performance of HPLC.
Materials and Methods

Patients and Samples
All patients with diabetes referred from June to October 2006 to Laboratorios Clínicos de Puebla, Puebla, Mexico, to have HbA 1c blood levels measured were included in this study. No further selection criteria were used, and the resulting study group was composed of 178 people with a median age of 54 years, ranging from 12 to 83 years. Of the 178 people, 94 (52.8%) were female. A fasting blood sample was obtained through venipuncture into sterile tubes containing the tripotassium salt EDTA K3 and processed within 2 hours for the measurement of HbA 1c .
Quantification of HbA 1c
This quantification was performed simultaneously in all cases by 2 commercially available techniques: the Bio-Rad D-10 Dual Program, a UV detection method using ion-exchange HPLC (Bio-Rad, Hercules, CA), and an immunoturbidimetric inhibition assay (Dimension, Dade Behring, Newark, DE).
Intra-assay and interassay coefficients of variation for the HPLC method are 0.8% and 0.7%, respectively. This system is designed also to detect and estimate levels of HbA 2 and fetal, S, C, D, J-Baltimore, O-Arab, H, and E hemoglobin variants 12 ; hence, the presence of any of these abnormalities was ruled out in all 178 subjects studied.
The intra-assay and interassay coefficients of variation of the immunoturbidimetric (IT) inhibition assay are 1.5% and 2.6%, respectively. 13, 14 The Bio-Rad D-10 Dual Program is based on chromatographic separation of hemoglobin fractions by ion-exchange HPLC; diluted samples are loaded onto the solid phase cartridge and gradually eluted with a bis-tris/phosphate buffer gradient of increasing ionic strength. The Dimension method consists of a turbidimetric inhibition assay in which a polyhapten reagent containing multiple HbA 1c epitopes competes with the sample's analyte for the binding sites of an anti-HbA 1c antibody. Determination by each method was performed in different areas of the laboratory by independent analysts who knew neither the experimental design nor the result of the other method. Both methods are currently certified by the National Glycohemoglobin Standardisation Program and are traceable to the International Federation of Clinical Chemistry and Laboratory Medicine reference method. 15 
Categorization of Patients According to Glycemic Control
Following recent recommendations from the American Diabetes Association, 2 patients were classified, according to their individual results by each method, into 2 categories: group 1, controlled (HbA 1c <7%) and group 2, uncontrolled (HbA 1c ≥7%). The frequency of each category for each method was compared, and the sensitivity, specificity, and positive and negative predictive values of the non-HPLC method to correctly categorize patients were estimated, considering the HPLC as the true result.
Statistical Analysis
Data were processed with the statistical software, SPSS, version 10 (SPSS, Chicago, IL). The mean and SD were presented as continuous variables, and categories were expressed as percentages. For comparison of the mean values, the t test was used, and for that of categories, the Spearman correlation test was selected. Deming regression analysis of individual values obtained from the 2 measuring methods was performed using the MedCalc program (MedCalc Software, Mariakerke, Belgium). The tetrachoric association coefficient and χ 2 were estimated with the aid of Epi Info software provided by the US Centers for Disease Control and Prevention. Sensitivity, specificity, and positive predictive values of the non-HPLC method were estimated with CATmaker software provided by the Oxford Evidence-Based Medicine Center, Oxford, England.
A copy of the results comparison was sent to the referring physicians of each of the 178 patients.
Results
The mean ± SD value of HbA 1c for the whole group was higher when measured by HPLC (8.01% ± 3.01%) than when estimated with the IT method (7.63% ± 2.17%; P < .05). When the patients were grouped by age decades, this difference was maintained except for patients younger than 20 years, for whom no statistical difference was observed (HPLC, 7.42% ± 2.9%; IT, 8.96% ± 4.34%; P > .05). According to the equation defined by the American Diabetes Association (28.7 × %HbA 1c -46.7), the estimated average ± SD glucose value for the whole group would be 183.22 ± 86.25 mg/dL according to the HPLC method and 173.32 ± 62.5 mg/dL if the immunoassay result is used for the calculation (P < .05).
❚Figure 1❚ shows that there was a significant linear correlation between the values measured by the HPLC and the IT methods; however, the equation values show that there is a positive bias of the immunoassay in regard to the chromatographic method and that increments measured by the latter are not linearly paralleled by the former.
The proportions of patients categorized into groups 1 and 2, respectively, were 46.1% and 53.9% by HPLC and 52.2% and 47.8% by the IT method. ❚Table 1❚ shows the degree of association between methods to categorize patients according to glycemic control. As shown, 21 (23%) of 93 patients were classified as controlled by the immunoassay when, in fact, according to the HPLC method, they were not. Conversely, 10 (12%) of 85 patients were erroneously classified as uncontrolled by the IT assay when their HbA 1c levels were less than 7% by the chromatographic method. Taken together, the total proportion of patients who were misclassified by the IT method was 17.4% (31/178).
❚Table 2❚ shows the differences in results of both methods in each of the 2 control categories, and ❚Figure 2❚ shows the same values (HPLC HbA 1c -IT HbA 1c ) in patients categorized by their HPLC result. It seems evident that the immunoassay underestimates HbA 1c levels when the real (HPLC) values are less than 7%, whereas it significantly overestimates such levels when the true concentrations are more than this value.
❚Table 3❚ shows the sensitivity, specificity, and positive and negative predictive values for the immunoassay for categorizing patients as belonging to group 1 or 2 according to the results of the reference (HPLC) method. Levels of HbA 1c of 8% or more were found in 70 (39.3%) of 178 patients included in the study; the sensitivity, specificity, and positive and negative predictive values of the IT method to identify the patients were 70%, 90%, 82%, and 82%, respectively. 
Discussion
Our results show that 2 different methods to measure the blood levels of HbA 1c , despite showing a statistically significant correlation, might differ in the categorization of the status of glycemic control of individual patients. This misclassification, in turn, might lead to erroneous decisions about treatment requirements or modifications. Within the group studied, 23% and 12% of the cases were classified by the immunoassay as controlled or uncontrolled, respectively, when, according to the reference method, they were in the opposite condition. It is needless to speculate on the consequences of these discrepancies in any given patient.
Among the different performance properties of any clinical laboratory test, those yielding predictive information are the most valuable; hence, the positive and negative predictive values are more informative than nosographic sensitivity and specificity. In our study group, the high prevalence of controlled patients (46.1%) might have biased these values, and it is possible that in a different population in which patients in glycemic control are scant, results might vary. Nevertheless, our study proves that the positive predictive value of the immunoassay to correctly identify patients in good control (77% [95% confidence interval 69%-86%]) is rather poor because it means that in 23% of the patients, no treatment modification is established because they are erroneously considered as "controlled" when actually they are not. In contrast, the positive predictive value of the immunoassay to identify uncontrolled patients is somewhat better (88% [95% confidence interval, 81%-95%]), but still, a treatment modification might be unnecessarily established in 12% of the patients who do not really need it.
Our results buttress the need to determine the nosographic performance values of alternative laboratory tests to measure blood levels of glycated hemoglobin, for these tests might have an important impact on individual clinical decisions. Reliance on the statistical significance of linear regression between the reference HPLC method and alternative methods is clearly unfounded.
